Trials / Completed
CompletedNCT01312714
Vitamin D3 Supplementation in Dialysis Patients
A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Regional Hospital Holstebro · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. This study will evaluate the effect of 26 weeks of vitamin D3 supplementation in patients with end stage renal disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cholecalciferol | 3 tablets of 1000 IU daily for 26 weeks |
| DRUG | Placebo | 3 tablets of 1000 IU daily for 26 weeks |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2011-03-11
- Last updated
- 2013-05-29
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01312714. Inclusion in this directory is not an endorsement.